Apoptosis drives cancer cells proliferate and metastasize

Journal of Cellular and Molecular Medicine

Volumn 17, Issue 1, 2013, Pages 205-211

  Wang, Rui An ^a,b   Li, Qin Long ^a,b   Li, Zeng Shan ^a,b   Zheng, Ping Ju ^c   Zhang, Hui Zhong ^a   Huang, Xiao Feng ^a   Chi, Su Min ^a   Yang, An Gang ^a   Cui, Rutao ^d  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c Chang'an Hospital   (China)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Cancer; Cell cycle; Inflammation; Metastasis; Stroma

Indexed keywords

APOPTOSIS REGULATORY PROTEIN;

APOPTOSIS; ARTICLE; CELL COUNT; CELL CYCLE; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; METASTASIS; MUTATION; NEOPLASM; PATHOLOGY; STROMA CELL; TUMOR GENE;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL COUNT; CELL CYCLE; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HUMANS; MUTATION; NEOPLASM METASTASIS; NEOPLASMS; STROMAL CELLS;

EID: 84873165697     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2012.01663.x     Document Type: Article

References (31)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000 100: 57-70.
2. Soto AM, Sonnenschein C. The tissue organization field theory of cancer: a testable replacement for the somatic mutation theory. BioEssays. 2011 33: 332-40.
3. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science. 2007 318: 1108-13.
4. Baserga R. The relationship of the cell cycle to tumor growth and control of cell division: a review. Cancer Res. 1965 25: 581-95.
5. Mendelsohn ML. Autoradiographic analysis of cell proliferation in spontaneous breast cancer of C3H mouse. III. The growth fraction. J Natl Cancer Inst. 1962 28: 1015-29.
6. Massague J. G1 cell-cycle control and cancer. Nature. 2004 432: 298-306.
7. Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood. 1992 80: 879-86.
8. Harris MH, Thompson CB. The role of the Bcl-2 family in the regulation of outer mitochondrial membrane permeability. Cell Death Differ. 2000 7: 1182-91.
9. Lipponen P, Aaltomaa S, Kosma VM, et al. Apoptosis in breast cancer as related to histopathological characteristics and prognosis. Eur J Cancer. 1994; 30A: 2068-73.
10. Lipponen P, Pietilainen T, Kosma VM, et al. Apoptosis suppressing protein bcl-2 is expressed in well-differentiated breast carcinomas with favourable prognosis. J Pathol. 1995 177: 49-55.
11. Lipponen P. Apoptosis in breast cancer: relationship with other pathological parameters. Endocr Relat Cancer. 1999 6: 13-6.
12. Nishimura R, Nagao K, Miyayama H, et al. Apoptosis in breast cancer and its relationship to clinicopathological characteristics and prognosis. J Surg Oncol. 1999 71: 226-34.
13. Sinicrope FA, Hart J, Michelassi F, et al. Prognostic value of bcl-2 oncoprotein expression in stage II colon carcinoma. Clin Cancer Res. 1995 1: 1103-10.
14. Sinicrope FA, Hart J, Hsu HA, et al. Apoptotic and mitotic indices predict survival rates in lymph node-negative colon carcinomas. Clin Cancer Res. 1999 5: 1793-804.
15. Vaquero J, Zurita M, Aguayo C, et al. Relationship between apoptosis and proliferation in secondary tumors of the brain. Neuropathology. 2004 24: 302-5.
16. Carrel A. Mechanism of the Formation and Growth of Malignant Tumors. Ann Surg. 1925 82: 1-13.
17. Fischer A. The theory of the developmental physiology of malignant tumors. Am J Cancer. 1937; 31: 1-20.
18. Tomita M, Matsuzaki Y, Edagawa M, et al. Prognostic significance of bcl-2 expression in resected pN2 non-small cell lung cancer. Eur J Surg Oncol. 2003 29: 654-7.
19. Callagy GM, Pharoah PD, Pinder SE, et al. Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin Cancer Res. 2006 12: 2468-75.
20. Rolland P, Spendlove I, Madjd Z, et al. The p53 positive Bcl-2 negative phenotype is an independent marker of prognosis in breast cancer. Int J Cancer. 2007 120: 1311-7.
21. Watson NF, Madjd Z, Scrimegour D, et al. Evidence that the p53 negative/Bcl-2 positive phenotype is an independent indicator of good prognosis in colorectal cancer: a tissue microarray study of 460 patients. World J Surg Oncol. 2005 19: 47.
22. Callagy GM, Webber MJ, Pharoah PD, et al. Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer. BMC Cancer. 2008; 8: 153.
23. Ali HR, Dawson SJ, Blows FM, et al. A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer. J Pathol. 2012 226: 97-107.
24. Poincloux L, Durando X, Seitz JF, et al. Loss of Bcl-2 expression in colon cancer: a prognostic factor for recurrence in stage II colon cancer. Surg Oncol. 2009 18: 357-65.
25. Murphy KL, Kittrell FS, Gay JP, et al. Bcl-2 expression delays mammary tumor development in dimethylbenz(a)anthracene-treated transgenic mice. Oncogene. 1999 18: 6597-604.
26. Chen L, Park SM, Tumanov AV, et al. CD95 promotes tumour growth. Nature. 2010 465: 492-6.
27. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010 140: 883-99.
28. Kuraishy A, Karin M, Grivennikov SI. Tumor promotion via injury- and death-induced inflammation. Immunity. 2011 35: 467-77.
29. Grivennikov SI, Karin M. Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann Rheum Dis. 2011 70: i104-8.
30. Sejima T, Morizane S, Hinata N, et al. Fas expression in renal cell carcinoma accurately predicts patient survival after radical nephrectomy. Urol Int. 2012; 88: 263-70.
31. Rui L, Schmitz R, Ceribelli M, et al. Malignant pirates of the immune system. Nat Immunol. 2011 12: 933-40.